メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
富山大学でコンテンツを検索
ホーム
プロファイル
研究部門
設備
プロジェクト
研究成果
データセット
受賞
活動
授業
Scopus著者プロファイル
林 龍二
教授, 博士(医学) 富山医科薬科大学 2000年3月
臨床腫瘍学講座
h-index
1571
被引用数
20
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1998 …
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(5)
研究成果
(106)
データセット
(2)
授業
(78)
類似のプロファイル
(6)
フィンガープリント
Ryuji Hayashiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Adverse Event
13%
Body Mass Index
13%
Bronchiolitis
28%
Bronchiolitis Obliterans Organizing Pneumonia
20%
Chemotherapy
44%
Chemotherapy
19%
Comorbidity
14%
Computer Assisted Tomography
23%
Disease
21%
Disease Course
38%
Diseases
18%
Epidermal Growth Factor Receptor
24%
Evans Syndrome
18%
Fibrosis
16%
Gefitinib
14%
Idiopathic Interstitial Pneumonia
28%
Immune Checkpoint Inhibitor
76%
Immunoglobulin G4
18%
Lactate Dehydrogenase
15%
Lung
80%
Lung Adenocarcinoma
49%
Lung Cancer
100%
Lung Carcinoma
17%
Malignant Neoplasm
19%
Messenger RNA
14%
Metastatic Carcinoma
15%
Mikulicz Disease
18%
Monotherapy
22%
Neoplasm
37%
Neutrophil
13%
Nivolumab
14%
Non Small Cell Lung Cancer
83%
Overall Survival
25%
Patient Characteristics
14%
Platinum
16%
Pleura Mesothelioma
14%
Prednisolone
24%
Prognostic Factor
18%
Programmed Death 1 Ligand 1
14%
Progression Free Survival
52%
Protein P53
13%
Recurrent Disease
22%
Retrospective Study
33%
Sarcomatoid Carcinoma
30%
Sirtuin1
18%
Small Cell Lung Cancer
39%
Systemic Therapy
14%
T-Helper Cell
16%
Thorax Radiography
15%
Tumor Cell
20%
Keyphrases
Bradykinin
18%
Bronchiolitis
18%
C-Jun N-terminal Kinase Signaling
18%
Chemotherapy
31%
Cisplatin
17%
Clinical Course
27%
Clinical Parameters
18%
Durvalumab
15%
Egfr
18%
EGFR mutation
24%
Elderly Patients
18%
Eosinophilic Pneumonia
18%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
18%
Hokushin Region
24%
Human Lung Fibroblasts
25%
Immune Checkpoint Inhibitors
30%
Immune Checkpoint Therapy
36%
Interleukin-6
20%
Interleukin-8
18%
Interstitial Pneumonia
16%
Ionizing Radiation
18%
Japan
26%
Lactate Dehydrogenase
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
32%
Lung
23%
Lung Adenocarcinoma
26%
Lung Cancer
74%
Lung Injury
26%
Monotherapy
32%
Multi-institutional Survey
30%
Neutrophil-to-lymphocyte Ratio
21%
Non-small Cell Lung Cancer (NSCLC)
95%
Non-squamous
16%
Older Men
25%
Overall Survival
21%
Patient Characteristics
18%
Patient Survival
16%
Performance Status
19%
Photo-cross-linker
18%
Prognostic Factors
25%
Programmed Death-ligand 1 (PD-L1)
15%
Programmed Death-ligand 1 Expression
20%
Progression-free Survival
56%
Pulmonary Sarcomatoid Carcinoma
24%
SIRT1 Activator
18%
Sirtuin 1 (SIRT1)
16%
Small Cell Lung Cancer
43%
Squamous Cell
16%
SRT1720
24%
Tumor
26%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
37%
Asthma
24%
Bradykinin
24%
Chemotherapy
18%
Chemotherapy Regimens
31%
Chronic Obstructive Lung Disease
12%
Cisplatin
22%
Creatinine
12%
Cystatin C
12%
Cytokine
21%
Daptomycin
12%
Disease Course
14%
Diseases
14%
Doxorubicin
12%
Durvalumab
15%
Epidermal Growth Factor Receptor
49%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Fatty Liver
12%
Gelatinase A
12%
Glutamate Sodium
12%
Immune Checkpoint Inhibitor
30%
Inflammation
20%
Interleukin 6
21%
Interleukin 8
24%
Ionizing Radiation
18%
Irinotecan
12%
Isoprenaline
12%
Lactate Dehydrogenase
18%
Loeffler Pneumonia
12%
Loss of Appetite
13%
Lung Cancer
61%
Malignant Neoplasm
26%
Messenger RNA
25%
Monotherapy
38%
Mouse Model
12%
Multidrug Resistance Associated Protein 1
12%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
36%
Naldemedine
12%
Neoplasm
24%
Non Small Cell Lung Cancer
70%
Overall Survival
24%
Phosphotransferase
25%
Placebo
12%
Programmed Death 1 Ligand 1
13%
Progression Free Survival
47%
Protein P53
15%
Recurrent Disease
16%
Retrospective Study
45%
Small Cell Lung Cancer
60%
Squamous Cell Lung Carcinoma
12%
